ATS Corp. Earnings Call: Growth Strong, Margins Pinched

Ats Corporation ((TSE:ATS)) has held its Q3 earnings call. Read on for the main highlights of the call.

ATS Corp.’s latest earnings call struck a cautiously upbeat tone, with management stressing strong revenue growth, expanding adjusted operating earnings, and a record backlog that underpins future demand. Executives acknowledged pressure from gross margin compression, softer bookings versus last year, and a weak Transportation segment, but framed these as manageable growing pains rather than structural setbacks.

Revenue Growth

ATS reported Q3 revenue of $761 million, up 16.7% year-over-year, with organic growth of about 12.6% and a 4.1% tailwind from foreign exchange. Year-to-date, revenue is up 13.6%, roughly 8% on an organic basis, underscoring broad-based momentum across the portfolio despite pockets of end-market softness.

Strong Profitability Improvement

Adjusted earnings from operations climbed to roughly $80 million in Q3, an impressive 21.6% increase from a year ago, outpacing revenue growth. Adjusted EPS came in at $0.48, highlighting the benefits of cost actions, mix management, and productivity initiatives even as certain contracts weighed on gross margin.

Robust Backlog and Book-to-Bill

The company closed the quarter with an order backlog of about $2.1 billion, providing healthy visibility into future revenue. A trailing 12-month book-to-bill ratio of 1.06 times signals that new orders continue to exceed shipments, suggesting sustained underlying demand.

Sequential Bookings Momentum

Q3 order bookings reached $821 million, up nearly 12% sequentially as activity improved across multiple end markets. Management emphasized that this sequential rebound supports a constructive demand outlook, even though current-quarter bookings lagged last year’s unusually strong comparison.

Life Sciences Strength

Life Sciences remains the engine of growth, with segment backlog at $1.1 billion and Q3 revenue of $391 million, the second-highest in ATS history. Ongoing momentum in radiopharma projects and GLP-1 auto-injector programs is reinforcing the segment’s role as a key driver of both growth and margin potential.

Energy Segment Acceleration

Energy posted a record order backlog of $296 million in Q3, up 87% from the same period last year, powered by nuclear refurbishment and life-extension work. ATS is also participating in new-build reactor initiatives, including small modular reactors, which could provide a long-duration, high-value pipeline for the segment.

Consumer and Food & Beverage Backlog

In Consumer Products, backlog hit a record $321 million, buoyed by a large enterprise warehouse packaging program that underscores ATS’s automation capabilities. Food & Beverage backlog reached $203 million, with a solid funnel of opportunities in core processing markets pointing to continued growth potential.

Cash Generation and Working Capital Progress

Operating cash flow was a strong $115 million in Q3, supporting reinvestment and balance sheet repair. Non-cash working capital improved to 16.4% of revenues, moving closer to management’s goal of under 15%, although payment timing still causes swings around quarter-end.

Capital Allocation and Balance Sheet Discipline

The company spent $16.6 million on capex and intangibles in Q3 and narrowed its fiscal 2026 spending outlook to $70–$90 million, signaling a disciplined approach. Net debt to adjusted EBITDA stands at about 3 times, trending toward the targeted 2–3 times range, and management is prioritizing selective M&A and high-return reinvestments.

Strategic and Organizational Moves

A new CEO, Doug Wright, is steering ATS toward leaner execution and margin expansion, with a sharper focus on its ABM methodology. Leadership additions in Life Sciences and Packaging & Food, along with integrating services into operating units, aim to boost recurring, higher-margin aftermarket revenue.

Gross Margin Compression

Despite earnings growth, gross margin slipped 111 basis points year-over-year to 29.6% in Q3, mainly due to program mix and timing. Management cited lower-margin nuclear projects as a headwind but argued that margin expansion initiatives and a richer services mix should offset these over time.

Bookings Down Versus Last Year

While bookings improved sequentially, Q3 orders were 7% below the prior-year quarter, reflecting a lower Transportation run rate and fewer large enterprise deals. Executives framed the decline as largely timing-related, given the prior year’s chunky wins, rather than a broad deterioration in demand.

Transportation Segment Weakness

Transportation revenue fell as expected and remains under pressure as ATS takes a cautious stance on new EV and transportation projects. The company is adopting a more targeted, selective approach in this segment, favoring opportunities that meet stricter return and risk criteria.

Rising SG&A and Cost Pressures

SG&A, excluding acquisition-related items, rose to $141.9 million in Q3, up $11.3 million year-over-year, driven by FX, higher employee costs, and professional fees. Stock-based compensation, excluding mark-to-market effects, was about $3.1 million, reflecting investments in talent as the company scales.

Restructuring and Execution Costs

ATS recorded $5.5 million in restructuring charges in Q3, and the program has been increased to roughly $20 million as more efficiency opportunities were identified. Management expects most of the savings to be realized in fiscal 2027, with some reinvested into higher-growth areas to support long-term expansion.

Working Capital Still Above Target

Although working capital metrics improved, non-cash working capital of 16.4% of revenues remains above the company’s sub-15% goal. Management noted that collection and payment timing can cause quarter-to-quarter volatility, but continued focus on cash discipline should gradually unlock additional liquidity.

Forward-Looking Guidance

For Q4, ATS guided revenue to a range of $710–$750 million, a step down from Q3’s $761 million that reflects timing and execution assumptions in its large backlog. The company reaffirmed its tighter fiscal 2026 capex and intangible spending range and highlighted leverage near 3 times EBITDA, signaling room for continued investment as restructuring benefits and backlog conversion flow through.

ATS’s earnings call portrayed a company balancing strong growth and record backlog against margin pressure and selective end-market softness. For investors, the story hinges on execution: if management can convert its sizable Life Sciences and Energy pipelines into higher-margin revenue while tightening working capital and delivering on restructuring, the current momentum could translate into durable value creation.